Premium
HaloTag‐Targeted Sirtuin‐Rearranging Ligand (SirReal) for the Development of Proteolysis‐Targeting Chimeras (PROTACs) against the Lysine Deacetylase Sirtuin 2 (Sirt2) **
Author(s) -
Schiedel Matthias,
Lehotzky Attila,
Szunyogh Sandor,
Oláh Judit,
Hammelmann Sören,
Wössner Nathalie,
Robaa Dina,
Einsle Oliver,
Sippl Wolfgang,
Ovádi Judit,
Jung Manfred
Publication year - 2020
Publication title -
chembiochem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.05
H-Index - 126
eISSN - 1439-7633
pISSN - 1439-4227
DOI - 10.1002/cbic.202000351
Subject(s) - sirtuin , ubiquitin ligase , sirt2 , ubiquitin , parkin , ubiquitin protein ligases , microbiology and biotechnology , proteolysis , cereblon , chemistry , dna ligase , sirtuin 1 , biochemistry , biology , nad+ kinase , enzyme , downregulation and upregulation , medicine , disease , pathology , parkinson's disease , gene
We have discovered the sirtuin‐rearranging ligands (SirReals) as a novel class of highly potent and selective inhibitors of the NAD + ‐dependent lysine deacetylase sirtuin 2 (Sirt2). In previous studies, conjugation of a SirReal with a ligand for the E3 ubiquitin ligase cereblon to form a so‐called proteolysis‐targeting chimera (PROTAC) enabled small‐molecule‐induced degradation of Sirt2. Herein, we report the structure‐based development of a chloroalkylated SirReal that induces the degradation of Sirt2 mediated by Halo‐tagged E3 ubiquitin ligases. Using this orthogonal approach for Sirt2 degradation, we show that other E3 ligases than cereblon, such as the E3 ubiquitin ligase parkin, can also be harnessed for small‐molecule‐induced Sirt2 degradation, thereby emphasizing the great potential of parkin to be used as an E3 ligase for new PROTACs approaches. Thus, our study provides new insights into targeted protein degradation in general and Sirt2 degradation in particular.